Qualigen Therapeutics Inc

-0.04 (-1.13%)
Earnings Announcements

Qualigen Therapeutics reports Q2 Loss Per Share $0.41

Published: 11/13/2020 14:10 GMT
Qualigen Therapeutics Inc (QLGN) - Qualigen Therapeutics Issues CEO Letter to Stockholders, Reports on Significant Progress and Fiscal Second Quarter Financial Results.
Q2 Loss per Share $0.41.
Q2 Revenue $800,000.
Qualigen Therapeutics - Has Necessary Capital to Fund Clinical Trial for As1411 and to Advance Pipeline Through Calendar Year 2021.
Revenue is expected to be $1.21 Million
Adjusted EPS is expected to be $0.03

Next Quarter Revenue Guidance is expected to be $1.41 Million
Next Quarter EPS Guidance is expected to be $0.07

More details on our Analysts Page.